What Didn’t Exist Three Years Ago
The American Association for Cancer Research (AACR) annual meeting highlighted the latest direction of early‑stage drug development. This year’s sessions featured two prostate‑cancer candidates using mechanisms that were not in the clinic just eighteen months ago. The preview spotlights a wave of novel modalities—such as RNA‑targeted agents and bispecific antibodies—aimed at metastatic disease. The personal relevance underscores the urgency, as metastatic prostate cancer remains a leading cause of mortality.
Novel Therapeutic and Trial Approaches for Lysosomal Storage Disorders with Polaryx’s Alex Yang — Episode 249
In episode 249 of the Xtalks Life Science Podcast, Alex Yang, JD, LLM, CEO of Polaryx, discusses the company’s mission to develop disease‑modifying small‑molecule therapies for rare pediatric lysosomal storage disorders. Yang leverages more than 25 years of experience across...
Loargys (Pegzilarginase) Wins FDA Nod for Ultrarare Metabolic Disorder After Earlier Setbacks
The U.S. FDA granted accelerated approval to Loargys (pegzilarginase‑nbln) for treating arginase‑1 deficiency (ARG1‑D), an ultrarare metabolic disorder affecting roughly 250 Americans. Loargys, a recombinant human arginase‑1 enzyme, is the first therapy shown to lower plasma arginine levels, achieving about...
Pharmaceutical Executive Daily: Trump Administration Delays Appeal of Federal Ruling Blocking Vaccine Policy Overhaul
The Trump administration has postponed filing an appeal against a federal judge’s injunction on RFK Jr.’s vaccine policy overhaul, citing internal debates over election‑year politics. Meanwhile, Biogen announced a $5.6 billion cash acquisition of Apellis Pharmaceuticals, paying $41 per share—a premium of...
Being Specific About Being General: Vaccines Edition
Emerging platforms are converging on a universal influenza vaccine, aiming to replace strain‑specific shots that require yearly reformulation. Companies such as Versatope are leveraging engineered bacterial outer‑membrane vesicles to deliver precise antigens, while NIH’s FluMos‑v2 expands hemagglutinin coverage to six...
A Deep Dive Into INN Proposed List 134
The World Health Organization released its International Nonproprietary Names (INN) Proposed List 134, introducing 124 new drug names slated for future approval. The list features a notable influx of antiviral and oncology agents, as well as the first biosimilar designations...
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of...
Vertex Pharmaceuticals announced that the U.S. FDA has approved label expansions for its CFTR modulators ALYFTREK and TRIKAFTA. ALYFTREK is now indicated for patients six years and older whose CFTR gene produces any functional protein, while TRIKAFTA’s indication now includes...
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with...
Zai Lab and Amgen have entered a global collaboration to test Zai Lab’s DLL3‑targeting antibody‑drug conjugate, zocilurtatug pelitecan (zoci), together with Amgen’s FDA‑approved bispecific T‑cell engager IMDELLTRA® in extensive‑stage small cell lung cancer (ES‑SCLC). Amgen will sponsor and lead a...
The New Infrastructure of Drug Commercialization
The pharmaceutical commercialization landscape is undergoing a rapid overhaul, driven by heightened government pricing controls, the rise of complex biologics, cell and gene therapies, and advanced data systems. Cold‑chain logistics have become a strategic priority as temperature‑sensitive products proliferate, while...
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Cyclerion Therapeutics and privately‑held Korsana Biosciences have signed an all‑stock merger agreement, creating a combined company that will operate as Korsana Biosciences and trade on Nasdaq under the ticker KRSA. Korsana secured an oversubscribed $380 million private placement that will fund...
The Biotech Bi-Weekly: Cell Barcoding, Compound Optimization and the Trillion Cell Atlas
The biotech sector is witnessing a wave of collaborations and product launches aimed at accelerating drug discovery and expanding genomic knowledge. Biotium introduced the ViaPlex™ 2‑Color Cell Barcoding Kit, enabling multiplex analysis of up to 15 cell populations in a...
Remaining Challenges in the Development of Partial Reprogramming Therapies
Partial reprogramming—brief exposure to Yamanaka factors OCT4, SOX2, KLF4 and MYC—has demonstrated modest rejuvenation in mouse studies but carries a substantial cancer risk if cells slip into full pluripotency. Funding is concentrated in a few well‑capitalized firms, notably Altos Labs,...
Productivity Enhancing Bioreactor for Scalable Organoid Culture
AMSBIO introduced RPMotion, a spinning organoid bioreactor that accelerates and automates 3‑D cell culture for drug discovery, disease modeling and regenerative medicine. The system delivers up to five‑fold faster organoid expansion while cutting reagent costs by roughly 60% and labor...
Regulating Payment of Participant Data in Clinical Trials
A team of scholars led by Steve Calandrillo proposes that FDA and IRBs adopt fair‑market‑value (FMV) payments for the data participants generate in clinical trials. Currently, participants receive modest compensation—about $4,000 per year—solely for trial involvement, not for the valuable...
BREAKING STUDY: Half of COVID-19 Vaccinated Military Personnel Suffered Subclinical Heart Stress
A new longitudinal study of 83 healthy military personnel tracked cardiac biomarkers after two mRNA COVID‑19 vaccine doses. Within two weeks of the second shot, 49% of participants exhibited a rise in NT‑proBNP exceeding 1.5 times their baseline, indicating subclinical...
AZD5004
Elecoglipron (ECC5004/AZD5004), an oral small‑molecule GLP‑1 receptor agonist, completed Phase 2 trials in type 2 diabetes and obesity, meeting primary endpoints in the SOLSTICE and VISTA studies. AstraZeneca licensed global rights from Eccogene for an upfront payment of $185 million and potential milestones...
CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed...
CellCentric has launched the pivotal Phase 2 DOMMINO‑1 trial of inobrodib 20 mg combined with pomalidomide and dexamethasone (InoPd) in heavily pretreated relapsed or refractory multiple myeloma (RRMM) patients. The first dose was administered at The Royal Marsden in London, with additional...
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion...
ImmunityBio secured $75 million of non‑dilutive financing under its existing royalty‑interest purchase agreement with Oberland Capital, raising total committed capital to $375 million. At the same time, Nant Capital converted $25 million of debt into common stock, reducing the company’s liabilities. The combined...
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium Abscessus Complex Lung Disease
AN2 Therapeutics has begun a Phase 2 investigator‑initiated trial of epetraborole, an oral leucyl‑tRNA synthetase inhibitor, for pulmonary disease caused by Mycobacterium abscessus. The randomized, double‑blind study will enroll 84 patients across roughly 10‑15 U.S. sites and is led by Dr. Kevin...
Is AI Ready to Transform COA Development?
Artificial intelligence is reshaping clinical development by augmenting, not replacing, human expertise. AI already accelerates medical imaging, compound discovery and COVID‑19 vaccine modeling, compressing timelines from years to months. In clinical outcome assessment (COA) translation, AI can support draft translation...
NVIDIA’s Healthcare Stack Is the Picks and Shovels Play You’ve Been Waiting For
NVIDIA has assembled a comprehensive AI infrastructure stack for healthcare, encompassing BioNeMo, MONAI, Isaac for Healthcare, Holoscan, Parabricks, Clara and NIM. Its 2026 State of AI in Healthcare survey shows 70% of organizations actively using AI, with generative models now...
The Ways Pharma Leaders Are Rewiring Their Organizations for Launch Success
Pharma executives face accelerating market pressure, prompting a shift from static launch plans to agile, data‑driven execution. Remco op den Kelder of Inizio Ignite argues that real‑time insights, AI integration, and cross‑functional collaboration are essential for successful product launches over...
The Ways Pharma Leaders Are Rewiring Their Organizations for Launch Success
Pharma executives face mounting pressure to deliver faster, more successful product launches amid volatile markets and tighter timelines. Inizio Ignite’s Global President Remco op den Kelder argues that traditional static launch plans must give way to agile, data‑driven execution models....
Dose by Design: Pharmaceutical 3D Printing and the Future of Pediatric Compounding
The article charts the transition of pharmaceutical 3D printing from research pilots to routine pharmacy practice, focusing on pediatric compounding. Companies such as FabRx and CurifyLabs have built platforms that let pharmacists print chewable tablets, gels, and mini‑tablets tailored to...
Can Damage to a Stressed Cell Be Reversed?
Soley Therapeutics’ co‑founder and CEO Dr. Yerem Yeghiazarians explained the company’s novel strategy of using small‑molecule drugs to reverse cellular stress rather than targeting a specific virus or gene. The platform aims to restore function in stressed cells implicated in non‑oncology...
Right Through the Skull
Researchers have unveiled a novel calvarial delivery platform that injects drug‑laden nanoparticles into the skull’s bone marrow. Immune cells within the diploic space capture the particles and migrate across skull‑meninges channels, ferrying the therapeutic cargo into the brain. In mouse...
Pharmaceutical Executive Daily: Eli Lilly Presses U.K. Government to Raise NHS Drug Pricing
Eli Lilly is pressuring the U.K. government to raise NHS drug prices and eliminate the VPAG rebate scheme before it resumes new investment in Britain. The company is also exploring outcome‑based pricing for its anti‑obesity medicines. In parallel, Lilly struck a...
What if Deleting the Oncogenic Protein Is the Wrong Move?
The article questions the prevailing belief that fully degrading oncogenic proteins outperforms merely inhibiting them. While inhibition has become a cornerstone of targeted cancer therapy, the piece argues that outright removal can trigger unforeseen biological responses. It highlights that protein...
Avutometinib and Defactinib
The FDA granted accelerated approval to the oral co‑pack Avutometinib and Defactinib for adults with KRAS‑mutated, recurrent low‑grade serous ovarian cancer (LGSOC) after prior therapy. The regimen pairs a RAF/MEK inhibitor with a FAK inhibitor, marking a rare “novel‑novel” combination...
InvestorTalk Alert: Brent Willis From Voyageur Pharmaceuticals Ltd. To Host on Tuesday, March 31, 2026
InvestorNews announced an InvestorTalk on March 31, 2026 at 9 AM EST featuring Brent Willis, President and CEO of Voyageur Pharmaceuticals Ltd. (TSXV:VM). Voyageur is advancing a vertically integrated strategy to produce barium and iodine contrast agents, highlighted by a 132,000‑tonne, 98.8% pure barium...
Eli Lilly Seeks Agreement with U.K. Government to Raise Prices for Medicines: Report
Eli Lilly is negotiating with the U.K. government to raise NHS drug prices and overhaul the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG). The company argues that current rebate rates of 25‑33% of revenues are unsustainable and threaten...
Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS
Prilenia Therapeutics and Ferrer have enrolled the first participant in PREVAiLS, a pivotal Phase 3, 500‑patient, randomized, placebo‑controlled trial of the sigma‑1 receptor agonist pridopidine for rapidly progressive ALS. The study, launched at Mass General Brigham, will span 48 weeks with...
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform
Meiji Seika Pharma announced a strategic investment in U.S. biotech Centivax to accelerate its universal influenza vaccine, Centi‑Flu 01, currently in Phase 1 trials. The partnership leverages Meiji’s pharmaceutical expertise and Centivax’s computational immune‑engineering platform to target conserved viral regions, aiming for...
Biocytogen Grants Taisho Pharmaceutical a License to Its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform
Biocytogen has licensed its RenNano® fully human heavy‑chain‑only antibody discovery platform to Japan’s Taisho Pharmaceutical, granting access to RenNano mice for in‑vivo generation and screening of VHH candidates. The agreement, whose financial terms remain undisclosed, adds to Biocytogen’s expanding portfolio...
Module 3, Section 1: HitID Screens
The module introduces HitID screens, outlining key strategies for early-stage drug discovery. It references recent literature on medicinal chemistry optimization, successful hit‑to‑clinical transitions, DNA‑encoded library (DEL) approaches, ultra‑low‑molecular‑weight crystallographic screening, and fragment‑based drug discovery (FBDD). By consolidating these sources, the...
A Novel G9a Inhibitor Reduces Symptoms in Mouse Models of Alzheimer's Disease
Researchers have unveiled FLAV-27, a novel G9a histone methyltransferase inhibitor that readily crosses the blood‑brain barrier and exhibits subnanomolar potency. The compound demonstrates high selectivity for G9a over related enzymes and a favorable safety profile, addressing the limitations of earlier...
Pharma Pulse: A Call for U.K. Pricing Reform and the Latest FDA-Approved Biosimilar for Bone Health
Eli Lilly is urging the United Kingdom to overhaul its drug‑pricing framework, warning that persistently low prices could deter future investment and calling for outcomes‑based reimbursement models, especially for obesity therapies. At the same time, the U.S. Food and Drug Administration...
FDA Launches New AI-Powered System to Track Drug and Vaccine Side Effects
The FDA launched the AI‑powered Adverse Event Monitoring System (AEMS) on March 11, 2026, consolidating VAERS, FAERS and other databases into a single, real‑time platform. AI automates data entry and categorization, replacing quarterly updates with instant reporting. Early testing showed...
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI
Rocket Pharmaceuticals received FDA approval on March 27 for KRESLADI, its first marketed product and the first gene therapy for a rare pediatric disorder. The clearance also awarded the company a Rare Pediatric Disease Priority Review Voucher, which can be...
Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026
Allogene Therapeutics announced that its lead CAR‑T candidate cema‑cel remains on schedule in the pivotal Phase 2 ALPHA3 trial for first‑line consolidation of large B‑cell lymphoma, now enrolling at more than 60 sites worldwide. An interim futility analysis is set for...
Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings
Aardvark Therapeutics announced on March 23, 2026 that it is voluntarily pausing its Phase 3 HERO trial of ARD‑101 for Prader‑Willi syndrome and the ARD‑201 obesity program while it consults the FDA. The decision follows cardiac findings in healthy‑volunteer studies, where...
The Risks of Direct-to-Consumer Pharmaceutical Advertising and Big Pharma
Direct-to-consumer (DTC) pharmaceutical advertising in the United States now commands $6‑8 billion in annual TV spend, propelling antipsychotics and biologics into mainstream consumer consciousness. Companies such as Eli Lilly and AbbVie have poured $30 million‑$24 million per month into campaigns for drugs like Rexulti...
Weekly Reads: Gattaca Stack, Animal Sacks, Custom iPS Cells, ImmunityBio FDA Warning, Mouse Cloning Limit
Weekly reads highlight several frontier biotech developments. The Gattaca Stack, a new database, tracks firms working on embryo models and artificial‑womb technologies. R3 Bio’s stem‑cell “organ sacks” aim to replace animal testing and could evolve into human organ bags, while...
Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously...
Kardigan reported positive Phase 2 data for its antisense drug tonlamarsen in the KARDINAL trial, showing a dose‑dependent 67% reduction in plasma angiotensinogen and a mean 6.7 mmHg drop in office systolic blood pressure after 20 weeks. Both a single 90 mg dose...
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College...
Arrowhead Pharmaceuticals presented two‑year open‑label extension data for plozasiran at the ACC 75th session, showing an 83% median triglyceride reduction in severe hypertriglyceridemia and 96% of patients dropping below the 500 mg/dL pancreatitis threshold. No adjudicated acute pancreatitis events occurred, and...
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition From Oral Atypical Antipsychotics to Cobenfy™ (Xanomeline and Trospium Chloride)
Bristol Myers Squibb reported Phase 4 data showing that adults with schizophrenia can switch from oral atypical antipsychotics to Cobenfy (xanomeline‑trospium) without loss of symptom control. In an 8‑week open‑label trial, 86% of 105 patients completed the study, and mean PANSS...
Statin Safety and Efficacy: What Recent Studies Reveal
Recent meta‑analyses of roughly 100,000‑plus adults confirm that statins and other cholesterol‑lowering drugs cut cardiovascular events by about 30 percent relative risk, delivering an absolute 2 percent mortality benefit over four years—equivalent to one life saved for every 50 treated. The safety...
LEO Pharma Announces New Long-Term Data for SPEVIGO® (Spesolimab-Sbzo) Injection in Adults with Generalized Pustular Psoriasis at AAD 2026
LEO Pharma presented long‑term results from the five‑year EFFISAYIL ON extension, showing subcutaneous SPEVIGO® reduced generalized pustular psoriasis (GPP) flares from an average of two per year to 0.13, with 74.6% of patients experiencing no flares over three years. Intravenous SPEVIGO...
How Does MFN Pricing Work Within TrumpRx?
TrumpRx, launched early 2026, is a direct‑to‑patient portal offering more than 40 drugs with cash‑pay prices, coupons and discounts. The platform aligns with the administration’s most‑favored‑nation (MFN) pricing policy, but the listed prices do not always match the official MFN...
VIVAZEN® Urges Immediate Action on 7-OH as U.S. House of Representatives Examines End Needless Distribution of 7-OH Act
VIVAZEN® welcomed a House Energy and Commerce subcommittee hearing on H.R. 8000, the End Needless Distribution of 7‑OH Act, urging the DEA to promptly schedule the synthetic opioid 7‑hydroxymitragynine. The company highlighted public‑health risks such as toxicity, dependence and market confusion...